Clinical trial
A Prospective Non-interventional Study Investigating the Treatment Effect of NovoMix® 30 (Biphasic Insulin Aspart 30) in a Real World Adult Population With Type 2 Diabetes in Algeria
NCT03862690 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Non-interventional Study Investigating the Treatment Effect of NovoMix® 30 (Biphasic Insulin Aspart 30) in a Real World Adult Population With Type 2 Diabetes in Algeria
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Observational
- Overall status
- Withdrawn
- Start date
- May 28, 2020
- Completion date
- June 28, 2021
- Enrollment
- 0 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.